# Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC

> **NCT07683832** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 50 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer NSCLC

## Interventions

- **BIOLOGICAL:** ABO2109 and toripalimab

## Key facts

- **NCT ID:** NCT07683832
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-28
- **Primary completion:** 2028-12-31
- **Final completion:** 2031-04-17
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07683832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07683832, "Safety, Tolerability, Immunogenicity, Pharmacodynamic Characteristics, and Preliminary Anti-tumor Activity of Personalized Cancer Vaccines Alone and in Combination With Toripalimab in Participants With Resected NSCLC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07683832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*